ERBB2 and neoplasm: Irrespective of the involved factors, this observation emphasizes the need to re-evaluate the HER2 status during the patient’s disease, even when the tumor was HER2-0 in a prior biopsy, potentially enabling access to T-Dxd treatment in case of a shift to HER2-low expression.